|
|
|
|
|
½ÃÀ庸°í¼
Ç×ü-¾à¹° º¹ÇÕü(2011³â) - ´Ù°¡¿À´Â ºñ¾àÀû Áøº¸ : ±â¼ú, ÀÌÇØ°ü°èÀÚ, ¿¬±¸ °³¹ß ÆÄÀÌÇÁ¶óÀÎ ºÐ¼®
Antibody-Drug Conjugates 2011 - real breakthrough still to come. A Technology, Stakeholder and R&D Pipeline Analysis
|
La Merie Publishing ¿¡¼ 2011³â 09¿ù ¿¡ ¹ßÇàÇÑ ¡¸Ç×ü-¾à¹° º¹ÇÕü(2011³â) - ´Ù°¡¿À´Â ºñ¾àÀû Áøº¸ : ±â¼ú, ÀÌÇØ°ü°èÀÚ, ¿¬±¸ °³¹ß ÆÄÀÌÇÁ¶óÀÎ ºÐ¼®¡¹ º¸°í¼´Â 274 Pages·Î ±¸¼ºµÇ¾î, US $2,632 ºÎÅÍ ±¸¸Å °¡´ÉÇÕ´Ï´Ù.
Ç×ü-¾à¹° º¹ÇÕü(Antibody-Drug Conjugates)¿¡¼ ÀÌ¿ëµÇ´Â ±â¼ú, ÀÌÇØ°ü°èÀÚ, ¿¬±¸°³¹ß ÆÄÀÌÇÁ¶óÀÎ, »ó¾÷Àû °¡Ä¡, ±â¾÷ °³¿ä µîÀ» Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù. Á¦4Àå Ç×ü-¾à¹° º¹ÇÕü¿¡¼ ÀÌ¿ëµÇ´Â ¾àÁ¦¿Í ¸µÄ¿ Á¦5Àå Ç×ü-¾à¹° º¹ÇÕü¿¡¼ ÀÌ¿ëµÇ´Â Ç×ü Á¦6Àå Ç×ü-¾à¹° º¹ÇÕüÀÇ ÀÌÇØ°ü°èÀÚ ºÐ¼® Á¦7Àå Ç×ü-¾à¹° º¹ÇÕüÀÇ ÀÓ»óÀû °¡Ä¡ Á¦8Àå Ç×ü-¾à¹° º¹ÇÕüÀÇ ¿¬±¸ °³¹ß ÆÄÀÌÇÁ¶óÀÎ ºÐ¼® Á¦9Àå Ç×ü-¾à¹° º¹ÇÕüÀÇ »ó¾÷Àû °¡Ä¡ Á¦10Àå ±â¾÷ °³¿ä - Abbott
- Aeterna Zentaris
- Allozyne
- Alpha Cancer Technologies
- Ambrx
- Amgen
- Amunix
- Anaphore
- Astellas Pharma (Agensys)
- AstraZeneca (MedImmune)
- Bayer Healthcare Pharmaceuticals
- Biogen Idec
- Biotest
- Bristol-Myers Squibb (Medarex)
- Celldex Therapeutics
- Centrose
- Daiichi-Sankyo
- Genmab
- GlaxoSmithKline
- ImmunoGen
- Immunomedics
- Merrimack Pharmaceuticals
- Mersana Therapeutics
- Millennium: The Takeda Oncology Company
- Nerviano Medical Sciences
- Novartis
- Pfizer (Wyeth)
- PharmaMar
- Philogen
- Progenics Pharmaceuticals
- Roche (Genentech)
- Sanofi
- Seattle Genetics
- Spirogen
- Sutro Biopharma
- Synthon (Syntarga)
- Tactic Pharma (Attenuon)
- Wilex (Heidelberg Pharma)
LSH
|

|